ArticleDiscover nano2025
Bio-fabricated silver nanoparticles: therapeutic evaluation as a potential nanodrug against cervical and liver cancer cells.
Article in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Are Silver and Gold Nanoparticles Obtained by 'Green' Synthesis Biocompatible?Nanomaterials (Basel, Switzerland) · 2026Review
- Postbiotic-Mediated Green Synthesis of Silver Nanoparticles: Revealing Potent Antimicrobial, Anti-Biofilm, Antioxidant, and Anticancer Properties using Paenibacillus xylanexedens.Probiotics and antimicrobial proteins · 2026Article
- Mechanistic evaluation of antibacterial and photocatalytic properties of biosynthesized silver nanoparticles against pathogenic bacteria and synthetic dyes.Discover nano · 2026Article
- Therapeutic Potential of Silver Nanoparticles in Hepatocellular Carcinoma: From Pathogenesis to Clinical Perspectives.International journal of nanomedicine · 2026Review
- Biosynthesis of silver and gold nanoparticles using cyanobacteria, their pharmaceutical and industrial applications.RSC advances · 2025Review
- Nanocarrier drug delivery systems for gynecological cancer therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2025Review
- Investigation of antifungal and antibiofilm activities of green synthesized silver nanoparticles against Candida glabrata.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanobiotechnology has grown rapidly and is now widely used in the diagnosis and treatment of modern diseases. Biosynthesized silver nanoparticles (AgNPs) are eco-friendly, cost-effective, biocompatible route, and have biomedical properties at minimal concentrations. In the present study extract of cyanobacterium (Anabaena variabilis) was utilized to synthesize facile, reliable AgNPs, further biosynthesized AgNPs were characterized by physicochemical techniques. The atomic force microscope study confirmed the shape of AgNPs while the scanning electron microscopy study revealed 17 to 35 nm in the size range. The zeta potential value of -19.5 mV demonstrated the repulsion effect between the particles, which prevents their aggregations while the heating stability of AgNPs was confirmed by Thermogravimetry differential thermal analysis. Another important characteristic, such as elemental constituent of AgNPs was determined by inductively coupled plasma mass spectrometry and was observed 94.24, 95.19, 97.06, and 99.34% of silver present in their respective concentrations of AgNPs. In vitro cytotoxicity of AgNPs was screened on HeLa, SiHa, (Cervical carcinoma), and HepG2 (Human hepatocellular carcinoma), cell lines. To evaluate the biocompatibility of AgNPs immortalized human embryonic kidney (HEK-293) cell line was used. The IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.